A feasibility study of alendronate therapy for osteonecrosis of the femoral head in adults with sickle cell disease

阿仑膦酸钠治疗成人镰状细胞病股骨头坏死的可行性研究

• 批准号: 10154739
• 负责人: Oyebimpe Oluyemisi Adesina
• 金额: $ 18.62万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10154739
• 关键词: Acute; Adherence; Adolescent; Adult; Adverse event; Affect; Age; Alendronate; Analgesics; Arthralgia; Biological Markers; Blood flow; Bone Density; Bone Diseases; Bone Pain; Bone Resorption; Bone necrosis; California; Child; Childhood; Chronic; Clinical; Clinical Investigator; Complication; Cyclophosphamide; Data; Enrollment; FDA approved; Feasibility Studies; Genotype; Goals; Head; Headache; Hematopoietic Stem Cell Transplantation; Incidence; Knowledge; Link; Measurement; Measures; Multicenter Studies; Operative Surgical Procedures; Oral; Oral cavity; Osteogenesis; Osteoporosis; Outcome Measure; Pain; Pain management; Patient Outcomes Assessments; Patients; Pharmaceutical Preparations; Phase; Phase II Clinical Trials; Phenotype; Physical therapy; Prospective cohort; Proxy; Public Health; Quality of life; Questionnaires; Replacement Arthroplasty; Reporting; Research; Research Project Grants; Research Training; Roentgen Rays; Safety; Serum; Sickle Cell; Sickle Cell Anemia; Specimen; Steroids; Study Subject; Surrogate Markers; Symptoms; System; Testing; Therapeutic; Time; Training Programs; Translational Research; Transplant Recipients; Trauma; Type I Procollagen; Urine; Vertebral column; Vitamin D; Work; arm; bisphosphonate; bone; bone turnover; career; chronic pain; clinical efficacy; cohort; disability; effective therapy; health related quality of life; hip surgery; improved; insight; ischemic injury; medication compliance; meetings; non-opioid analgesic; opioid use; pain relief; pain score; post-transplant; prevent; primary endpoint; programs; randomized placebo controlled trial; recruit; retention rate; secondary endpoint; sex; side effect; skeletal; skills; targeted treatment; translational study; transplantation therapy

PROJECT SUMMARY/ABSTRACT Osteonecrosis of the femoral head (ONFH) is a serious skeletal complication that affects 30% of people living with sickle cell disease (SCD). ONFH causes severe chronic pain and permanent disability. ONFH symptoms persist even after curative hematopoietic stem cell transplant therapy, with post-transplant patients reporting poorer quality of life due to their skeletal limitations. There is an urgent need to explore effective therapies for ONFH to relieve pain and improve the health-related quality of life for people with SCD. Alendronate, an oral bisphosphonate that is FDA-approved for treatment of osteoporosis, decreased bone pain and delayed the time to femoral head collapse in people with steroid-induced and traumatic ONFH. The therapeutic potential of alendronate to alleviate bone pain in adults with SCD-related ONFH is an important gap in knowledge with far-reaching public health implications. My colleagues and I recently showed that low bone density, another prevalent skeletal complication of SCD, associates with ONFH and chronic pain in children and adolescents with SCD. I speculate that the association between low bone density, ONFH and sickle cell pain will be even more significant in adults since many SCD complications worsen with age. In this K23 resubmission, I plan to study the pain phenotype of adults with SCD and low bone density using a validated patient-reported outcome measure. I will also conduct a single-arm 6- month feasibility study of alendronate in a prospective cohort of 24 adults with SCD-related ONFH. The primary endpoints are predetermined recruitment and retention rates. Secondary endpoints include preliminary safety and efficacy, as measured by adverse events reporting, medication adherence, opioid use, change in pain scores and other surrogate markers. Lastly, I will collect serum and urine specimens from a subset of non-transfused study subjects to better understand how bone biomarkers can be used a proxy for alendronate adherence and to study how bone biomarker concentrations correlate with underlying SCD bone pathobiology. Repurposing alendronate as targeted therapy for SCD-related ONFH can reduce opioid use and improve health-related quality of life for people with SCD. This revised K23 proposal will lay the groundwork for a subsequent R01 application for a Phase 2 multicenter, randomized, placebo-controlled trial of alendronate in adults with SCD complicated by ONFH. My work will significantly add to ongoing clinical-translational studies to reduce the burden of chronic pain in people living with SCD. The research and training program detailed in my K23 application will provide me with the critical skills I need to build my career as an independent, clinical investigator engaged in developing safe and effective therapies for people with SCD.

项目摘要/摘要 股骨头（ONFH）的骨坏死是一种严重的骨骼并发症，影响30％的生活 镰状细胞疾病（SCD）。 ONFH会导致严重的慢性疼痛和永久性残疾。 onfh 即使在治愈造血干细胞移植治疗后，症状仍然存在，移植后患者 报告由于其骨骼限制而导致的生活质量较差。迫切需要探索有效 ONFH的治疗方法可以缓解疼痛并改善SCD患者的健康相关生活质量。 Alendronate， FDA批准用于治疗骨质疏松症的口服双膦酸盐，减轻骨痛并延迟 类固醇引起和创伤性的人的股骨头倒塌的时间。治疗潜力 与SCD相关的ONFH的成年人的alendronate的骨骼疼痛是一个重要的知识差距 深远的公共卫生影响。 我和我的同事最近表明，SCD的另一个普遍的骨骼并发症，低骨密度， 与SCD的儿童和青少年的ONFH和慢性疼痛有关。我推测协会 在低骨密度，ONFH和镰状细胞疼痛之间，由于许多SCD 并发症随着年龄的增长而恶化。在此K23重新提交中，我计划研究SCD成年人的疼痛表型 使用经过验证的患者报告的结局指标和低骨密度。我还将进行单臂6- Alendronate的月份可行性研究在24名与SCD相关的成年人组成的前瞻性队列中。主要 终点是预定的招聘和保留率。次要终点包括初步安全 和功效，通过不良事件报告，药物依从性，阿片类药物的使用，疼痛评分的变化来衡量 和其他替代标记。最后，我将从非转移的子集收集血清和尿液标本 研究受试者更好地了解如何使用骨骼生物标志物作为抗逆转岩的依从性和 研究骨生物标志物浓度如何与潜在的SCD骨病理学相关。 重新利用Alendronate作为SCD相关ONFH的有针对性疗法可以减少阿片类药物的使用并改善 SCD患者的健康相关生活质量。该修订后的K23提案将为A奠定基础 随后的R01应用2期多中心，随机，安慰剂对照试验的Alendronate试验 在患有SCD的成年人中，ONFH复杂。我的工作将大大增加正在进行的临床翻译 减轻SCD患者慢性疼痛负担的研究。研究与培训计划 在我的K23应用程序中详细介绍将为我提供建立职业所需的关键技能 独立的临床研究人员为SCD患者开发安全有效的疗法。